These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19307693)

  • 41. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.
    Jia G; Aroor AR; Sowers JR
    Cardiovasc Res; 2017 Jul; 113(9):1055-1063. PubMed ID: 28838041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
    Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
    Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT; Rocha R; Chander PN
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors.
    Lemarié CA; Simeone SM; Nikonova A; Ebrahimian T; Deschênes ME; Coffman TM; Paradis P; Schiffrin EL
    Circ Res; 2009 Oct; 105(9):852-9. PubMed ID: 19762686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease.
    Parker BM; Wertz SL; Pollard CM; Desimine VL; Maning J; McCrink KA; Lymperopoulos A
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease.
    Pantelidis P; Sideris M; Viigimaa M; Avranas K; Deligkaris P; Zografou I; Lovic D
    Curr Pharm Des; 2018; 24(46):5491-5499. PubMed ID: 30767735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the aldosterone pathway in cardiovascular disease.
    Gustafsson F; Azizi M; Bauersachs J; Jaisser F; Rossignol P
    Fundam Clin Pharmacol; 2012 Feb; 26(1):135-45. PubMed ID: 22044496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.
    Joffe HV; Adler GK
    Heart Fail Rev; 2005 Jan; 10(1):31-7. PubMed ID: 15947889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific Activation of the Alternative Cardiac Promoter of
    Mesquita TR; Auguste G; Falcón D; Ruiz-Hurtado G; Salazar-Enciso R; Sabourin J; Lefebvre F; Viengchareun S; Kobeissy H; Lechène P; Nicolas V; Fernandez-Celis A; Gómez S; Lauton Santos S; Morel E; Rueda A; López-Andrés N; Gómez AM; Lombès M; Benitah JP
    Circ Res; 2018 Mar; 122(7):e49-e61. PubMed ID: 29467196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
    Jaisser F; Farman N
    Pharmacol Rev; 2016 Jan; 68(1):49-75. PubMed ID: 26668301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extrarenal effects of aldosterone.
    Nguyen Dinh Cat A; Jaisser F
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):147-56. PubMed ID: 22240440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and role of aldosterone receptors in the cardiovascular system.
    Lombès M; Farman N; Bonvalet JP; Zennaro MC
    Ann Endocrinol (Paris); 2000 Feb; 61(1):41-6. PubMed ID: 10790591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale for the use of aldosterone antagonists in congestive heart failure.
    Rocha R; Williams GH
    Drugs; 2002; 62(5):723-31. PubMed ID: 11929327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
    Lakkis J; Lu WX; Weir MR
    Curr Hypertens Rep; 2003 Oct; 5(5):408-17. PubMed ID: 12948434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endothelial Dysfunction in Primary Aldosteronism.
    Chen ZW; Tsai CH; Pan CT; Chou CH; Liao CW; Hung CS; Wu VC; Lin YH;
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats.
    Wang HW; Huang BS; Chen A; Ahmad M; White RA; Leenen FH
    Neuroscience; 2016 Feb; 314():90-105. PubMed ID: 26656220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.